MCID: CLP006
MIFTS: 45

Clopidogrel Resistance

Categories: Blood diseases, Metabolic diseases

Aliases & Classifications for Clopidogrel Resistance

MalaCards integrated aliases for Clopidogrel Resistance:

Name: Clopidogrel Resistance 26
Cyp2c19-Related Poor Drug Metabolism 26
Poor Metabolism of Clopidogrel 26
Resistance to Clopidogrel 26

Classifications:



Summaries for Clopidogrel Resistance

Genetics Home Reference : 26 Clopidogrel resistance is a condition in which the drug clopidogrel is less effective than normal in people who are treated with it. Clopidogrel (also known as Plavix) is an antiplatelet drug, which means that it prevents blood cell fragments called platelets from sticking together (aggregating) and forming blood clots. This drug is typically given to prevent blood clot formation in individuals with a history of stroke; heart attack; a blood clot in the deep veins of the arms or legs (deep vein thrombosis); or plaque buildup (atherosclerosis) in the blood vessels leading from the heart, which are opened by placement of a small thin tube (stent).

MalaCards based summary : Clopidogrel Resistance, also known as cyp2c19-related poor drug metabolism, is related to drug metabolism, poor, cyp2c19-related and myocardial infarction. An important gene associated with Clopidogrel Resistance is CYP2C19 (Cytochrome P450 Family 2 Subfamily C Member 19), and among its related pathways/superpathways are Metabolism and Cytochrome P450 - arranged by substrate type. The drugs Clopidogrel and Atorvastatin have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and whole blood, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Clopidogrel Resistance

Graphical network of the top 20 diseases related to Clopidogrel Resistance:



Diseases related to Clopidogrel Resistance

Symptoms & Phenotypes for Clopidogrel Resistance

MGI Mouse Phenotypes related to Clopidogrel Resistance:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.86 ABCB1 CYP1A1 CYP1A2 ITGB3 KDR PTGS2
2 hematopoietic system MP:0005397 9.81 ABCB1 CYP1A1 ITGB3 KDR P2RY1 P2RY12
3 homeostasis/metabolism MP:0005376 9.7 ABCB1 CYP1A1 CYP1A2 HMGCR ITGB3 KDR
4 liver/biliary system MP:0005370 9.23 ABCB1 CYP1A1 CYP1A2 HMGCR ITGB3 KDR

Drugs & Therapeutics for Clopidogrel Resistance

Drugs for Clopidogrel Resistance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
2
Atorvastatin Approved Phase 4 134523-00-5 60823
3
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
4
Ticagrelor Approved Phase 4,Phase 3,Phase 2 274693-27-5 9871419
5
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
6
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
7
Tirofiban Approved Phase 4 144494-65-5 60947
8
Cilostazol Approved, Investigational Phase 4,Not Applicable 73963-72-1 2754
9
Histamine Approved, Investigational Phase 4 51-45-6 774
10
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
11
Pantoprazole Approved Phase 4 102625-70-7 4679
12
Sodium Citrate Approved, Investigational Phase 4 68-04-2
13
Ranitidine Approved Phase 4 66357-59-3, 66357-35-5 3001055
14
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
15
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
16
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
17 Purinergic P2Y Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
19 Lipid Regulating Agents Phase 4
20 Anticholesteremic Agents Phase 4
21 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antimetabolites Phase 4
23 Calcium, Dietary Phase 4
24 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Purinergic P2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Hypolipidemic Agents Phase 4
27 Rosuvastatin Calcium Phase 4 147098-20-2
28 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
29 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Not Applicable
30 Antipyretics Phase 4,Phase 3,Not Applicable
31 Cyclooxygenase Inhibitors Phase 4,Phase 3,Not Applicable
32 Anti-Inflammatory Agents Phase 4,Phase 3,Not Applicable
33 Antirheumatic Agents Phase 4,Phase 3,Not Applicable
34 Analgesics, Non-Narcotic Phase 4,Phase 3,Not Applicable
35 Analgesics Phase 4,Phase 3,Not Applicable
36 Fibrinolytic Agents Phase 4,Phase 3,Not Applicable
37 Prasugrel hydrochloride Phase 4,Phase 3 389574-19-0
38 Adjuvants, Immunologic Phase 4
39 Antibiotics, Antitubercular Phase 4
40 interferons Phase 4
41 Anti-Bacterial Agents Phase 4
42 Interferon Inducers Phase 4
43 polysaccharide-K Phase 4
44 Anti-Infective Agents Phase 4
45 calcium heparin Phase 4
46 Radiation-Protective Agents Phase 4
47 Immunologic Factors Phase 4
48 Antiviral Agents Phase 4
49 Protective Agents Phase 4,Not Applicable
50 Vasodilator Agents Phase 4,Not Applicable

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized and Cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction Unknown status NCT02411903 Phase 4 atorvastatin and clopidogrel;rosuvastatin and clopidogrel
2 Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance Completed NCT00398463 Phase 4 Tirofiban;Placebo
3 Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation Completed NCT01094457 Phase 4 aspirin, clopidogrel;aspirin, clopidogrel, cilostazol
4 Study of Policosanol to Improve Platelet Reactivity After Percutaneous Coronary Stent Implantation (PCI) Completed NCT01371058 Phase 4 high maintenance clopidogrel;routine dual antiplatelet;policosanol plus dual antiplatelet
5 Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Completed NCT00262561 Phase 4 Aspirin
6 Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention Completed NCT00404781 Phase 4 cilostazol in addition to aspirin and clopidogrel
7 Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects Completed NCT00930670 Phase 4 Rosuvastatin-omeprazole;Rosuvastatin-pantoprazole;Rosuvastatin-esomeprazole;Rosuvastatin-ranitidine;Atorvastatin-omeprazole;Atorvastatin-pantoprazole;Atorvastatin-esomeprazole;Atorvastatin-ranitidine
8 Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD Recruiting NCT03614832 Phase 4 Ticagrelor 90 mg;Clopidogrel 150 mg
9 Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm Recruiting NCT03581409 Phase 4 Aspirin;Prasugrel;Clopidogrel;Cilostazol
10 Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents Withdrawn NCT00589862 Phase 4 Plavix (Clopidogrel)
11 Clopidogrel Resistance and Embolism in Carotid Artery Stenting Unknown status NCT02133989 Phase 3 Ticlopidine + Ginko biloba;Clopidogrel
12 Efficacy and Safety Study of Ticagrelor Unknown status NCT01812330 Phase 3 Clopidogrel;Ticagrelor
13 ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery Unknown status NCT01046942 Phase 3 Clopidogrel+acetylsalicylic acid;acetylsalicylic acid
14 The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance Completed NCT01032668 Phase 3 Clopidogrel
15 Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI). Completed NCT01109784 Phase 3 prasugrel;clopidogrel
16 Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS Completed NCT00444132 Phase 3 clopidogrel
17 Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis Completed NCT01155765 Phase 3 Prasugrel;Clopidogrel
18 Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment Completed NCT01304472 Phase 3 Prasugrel;Clopidogrel
19 Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity Recruiting NCT03062462 Phase 2, Phase 3 Clopidogrel;ticagrelor
20 Antiplatelet Effects of Low-dose Ticagrelor and Standard-dose Clopidogrel in Chinese ACS Patients Recruiting NCT03381742 Phase 2, Phase 3 Ticagrelor;ticagrelor;ticagrelor;clopidogrel
21 Clopidogrel Pharmacogenomics Project Completed NCT01097343 Phase 2 clopidogrel 75 mg;Clopidogrel 150 mg
22 Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant Withdrawn NCT02008123 Phase 2 Primidone
23 Impact of Citalopharm and Fluvoxamine on Platelet Response to Clopidogrel Completed NCT01396720 Phase 1 fluvoxamine;citalopharm
24 Optimal Regimen in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance Unknown status NCT01925872
25 Effects of RF on Clopidogrel Resistance in Patients at High Cardiovascular Risk Unknown status NCT02624583
26 Clopidogrel Resistance and Platelet Reactivity in Women Undergoing Percutaneous Coronary Intervention Unknown status NCT01796873
27 Thromboelastography As A Tool for Possible Clopidogrel Resistance in The Patients Treated With Primary PCI for STEMI Unknown status NCT00517478
28 Prasugrel Versus Clopidogrel in Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) Unknown status NCT01090336
29 Multiple Electrode Aggregometry & Clopidogrel Resistance Completed NCT01991093
30 Aspirin and Clopidogrel Resistance Study Completed NCT01039480
31 Resistance on Antithrombotic Drugs in Ischemic Heart Disease Completed NCT00742430
32 Prevalence of Clopidogrel (Plavix) Resistance in Hemodialysis Patients Completed NCT01865890
33 clOpidogrel "resIstaNce" in a Selected Population of Patients at a Tertiary Cardiovascular Center in Trinidad Completed NCT03667066 Clopidogrel
34 The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol Completed NCT00620646 Not Applicable aspirin, clopidogrel;aspirin, clopidogrel, cilostazol
35 Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention) Completed NCT02101411
36 Perioperative Aspirin Response in Patients Undergoing Vascular Surgery Completed NCT03587324 Not Applicable Whole blood aggregometry before and after vascular treatment (ASA/ Clopidogrel).
37 Correlation Between Laboratory Markers and Origin of New Brain Ischemic Lesions After Carotid Stenting Completed NCT02310191
38 Endovascular Treatment of Atherosclerotic Lesions in the SFA Using the Sinus-superflex-635 Stent Completed NCT01816854
39 Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery Recruiting NCT02184884
40 Clopidogrel Resistance in Stroke Patients From Different Ethnicities Not yet recruiting NCT03806894
41 ASA- and Clopidogrel-Responsiveness in Patients With Peripheral Arterial Occlusive Disease and Interventional Procedures Suspended NCT00593762
42 Clopidogrel Resistance and the Possibility of Its Affection Temporarily not available NCT00839345 clopidogrel

Search NIH Clinical Center for Clopidogrel Resistance

Genetic Tests for Clopidogrel Resistance

Anatomical Context for Clopidogrel Resistance

MalaCards organs/tissues related to Clopidogrel Resistance:

42
Heart, Testes, Whole Blood, Brain, Kidney

Publications for Clopidogrel Resistance

Articles related to Clopidogrel Resistance:

(show top 50) (show all 183)
# Title Authors Year
1
Low-dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms: Follow-up of over 6 Months. ( 30827067 )
2019
2
Comparison of Clopidogrel and Ticlopidine/Ginkgo Biloba in Patients With Clopidogrel Resistance and Carotid Stenting. ( 30761076 )
2019
3
Platelet Surface CD62p and Serum Vitamin D Levels are Associated with Clopidogrel Resistance in Chinese Patients with Ischemic Stroke. ( 30795966 )
2019
4
Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease. ( 30891852 )
2019
5
Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy. ( 29915438 )
2018
6
A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients. ( 29347970 )
2018
7
Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients. ( 29350207 )
2018
8
Comment on "Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients". ( 29424732 )
2018
9
Low-Dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms. ( 30196683 )
2018
10
The Impact of Clopidogrel Resistance on Clinical Outcome of Iranian Patients Undergoing Percutaneous Coronary Intervention. ( 30127832 )
2018
11
Is Preoperative Clopidogrel Resistance a Predictor of Bleeding and Risks in Patients Undergoing Emergency CABG Surgery? ( 30184029 )
2018
12
Investigating the Effect of Demographics, Clinical Characteristics, and Polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on Clopidogrel Resistance. ( 30422888 )
2018
13
Clopidogrel Resistance in Lower Extremity Arterial Endovascular Interventions. ( 30621557 )
2018
14
Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome. ( 28383427 )
2017
15
P2Y12 receptor gene polymorphism and the risk of resistance to clopidogrel: A meta-analysis and review of the literature. ( 28791856 )
2017
16
Prevalence of older in-patients at risk of clopidogrel resistance according to the STIB score. Results from REPOSI registry. ( 28410858 )
2017
17
The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population. ( 28358842 )
2017
18
Overcoming clopidogrel resistance: Three promising novel antiplatelet drugs developed in China. ( 28817486 )
2017
19
Review of aspirin and clopidogrel resistance in peripheral arterial disease. ( 28893489 )
2017
20
Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance. ( 28329746 )
2017
21
A Novel Multiplex HRM Assay to Detect Clopidogrel Resistance. ( 29167499 )
2017
22
Obesity, leptin, and thrombosis: Focus on clopidogrel resistance. ( 27774960 )
2016
23
Effects of genetic factors to stent thrombosis due to clopidogrel resistance after coronary stent placement. ( 26828987 )
2016
24
Effect of Shexiang baoxin pills on clopidogrel resistance in patients with acute coronary syndrome. ( 28167470 )
2016
25
Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism. ( 27555873 )
2016
26
Potent and Orally Bioavailable Antiplatelet Agent, PLD-301, with the Potential of Overcoming Clopidogrel Resistance. ( 27594816 )
2016
27
Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese Population. ( 26935114 )
2016
28
Expression of miRNA-26a in platelets is associated with clopidogrel resistance following coronary stenting. ( 27347088 )
2016
29
Effect of obesity and serum leptin level on clopidogrel resistance. ( 27774962 )
2016
30
Allele Frequency Distribution of CYP2C19 Genotypes Associated with Clopidogrel Resistance in Russian Population. ( 27673643 )
2016
31
Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. ( 26961113 )
2016
32
Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke. ( 27133299 )
2016
33
Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis? ( 26340464 )
2016
34
A new approach: Left atrial appendage occlusion, as an alternative to anticoagulant, to treat patient who suffered of atrial fibrillation, acute coronary syndrome and clopidogrel resistance. ( 26479956 )
2016
35
Tailored antiplatelet therapy in a patient with ITP and clopidogrel resistance. ( 25428265 )
2015
36
Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism. ( 25452814 )
2015
37
[CLINICAL AND PHARMACOLOGICAL FACTORS INFLUENCING RESISTANCE TO CLOPIDOGREL IN PATIENTS WITH CARDIOVASCULAR DISEASES]. ( 26117917 )
2015
38
Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients? ( 25893489 )
2015
39
Clopidogrel resistance after renal transplantation. ( 25792661 )
2015
40
Clopidogrel Resistance after Minor Ischemic Stroke or Transient Ischemic Attack is Associated with Radiological Cerebral Small-Vessel Disease. ( 26303791 )
2015
41
Clopidogrel resistance response in patients with coronary artery disease and metabolic syndrome: the role of hyperglycemia and obesity. ( 26347447 )
2015
42
Allele frequency distribution of CYP2C19*2 allelic variants associated with clopidogrel resistance in cardiac patients. ( 26170954 )
2015
43
The STIB score: a simple clinical test to predict clopidogrel resistance. ( 26567810 )
2015
44
Relation between the Change in Mean Platelet Volume and Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Intervention. ( 25322834 )
2015
45
Association of VEGFR-2 Gene Polymorphisms With Clopidogrel Resistance in Patients With Coronary Heart Disease. ( 25738571 )
2015
46
Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease. ( 26264906 )
2015
47
Clopidogrel Resistance in Neurovascular Stenting: Correlations between Light Transmission Aggregometry, VerifyNow, and the Multiplate. ( 26272977 )
2015
48
High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. ( 24913197 )
2015
49
VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke. ( 25457586 )
2014
50
Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients. ( 24745016 )
2014

Variations for Clopidogrel Resistance

Expression for Clopidogrel Resistance

Search GEO for disease gene expression data for Clopidogrel Resistance.

Pathways for Clopidogrel Resistance

Pathways related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 ABCB1 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2
2
Show member pathways
13.19 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
3
Show member pathways
12.82 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
4
Show member pathways
12.18 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 PTGS2
5 12.03 ITGB3 P2RY1 P2RY12 VASP
6
Show member pathways
12 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4 PTGS2
7 11.98 CYP2C19 CYP2C9 CYP2J2 PTGS2
8
Show member pathways
11.98 ABCB1 CYP2C19 CYP2C9 CYP3A4 CYP3A5
9
Show member pathways
11.92 ITGB3 KDR PTGS2
10
Show member pathways
11.89 CYP1A1 CYP1A2 CYP2C19 CYP2J2 CYP3A4
11 11.8 ITGB3 KDR PTGS2
12
Show member pathways
11.74 CYP1A1 CYP1A2 CYP3A4
13 11.7 ABCB1 CYP3A4 HMGCR
14
Show member pathways
11.7 CYP1A1 CYP1A2 CYP3A4 CYP3A5
15
Show member pathways
11.69 ABCB1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
16
Show member pathways
11.65 ABCB1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
17
Show member pathways
11.58 ABCB1 CYP3A4 CYP3A5
18
Show member pathways
11.58 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
19 11.52 CYP1A1 CYP2J2 PTGS2
20 11.51 CYP1A1 CYP1A2 PTGS2
21
Show member pathways
11.44 ABCB1 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4
22 11.39 CYP1A1 CYP1A2 CYP2C19
23
Show member pathways
11.39 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
24 11.38 ABCB1 CYP1A2 CYP2C9 CYP3A4
25
Show member pathways
11.35 CYP1A1 CYP1A2 CYP3A4
26 11.34 ABCB1 CYP2C19 CYP2C9 CYP3A4 CYP3A5
27
Show member pathways
11.24 CYP1A2 CYP2C9 CYP3A4
28
Show member pathways
11.22 CYP2C9 CYP2J2 PTGS2
29 11.19 CYP1A1 CYP1A2 CYP2C9 CYP3A4
30 11.15 CYP1A2 CYP3A4 CYP3A5
31 11.08 ABCB1 CYP2C9 CYP3A4
32
Show member pathways
11.01 ABCB1 CYP1A1 CYP1A2 CYP2C9 CYP3A4 CYP3A5
33
Show member pathways
10.98 CYP1A1 CYP1A2 CYP3A4
34 10.95 ABCB1 CYP3A4 CYP3A5 PTGS2
35 10.94 ABCB1 CYP3A4 CYP3A5
36 10.93 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5 ITGB3
37 10.91 ABCB1 CYP3A4
38 10.87 ABCB1 CYP3A4 CYP3A5
39 10.79 CYP1A1 CYP1A2
40 10.73 ABCB1 CYP3A4 CYP3A5
41 10.51 CYP2C9 CYP2J2

GO Terms for Clopidogrel Resistance

Cellular components related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.96 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
2 endoplasmic reticulum membrane GO:0005789 9.81 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
3 intracellular membrane-bounded organelle GO:0043231 9.61 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
4 lamellipodium membrane GO:0031258 9.43 ITGB3 VASP
5 filopodium membrane GO:0031527 9.4 ITGB3 VASP
6 platelet alpha granule membrane GO:0031092 9.37 ITGB3 SELP
7 organelle membrane GO:0031090 9.23 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
8 membrane GO:0016020 10.22 ABCB1 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2

Biological processes related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.97 ABCB1 CYP1A1 CYP1A2 PTGS2
2 xenobiotic metabolic process GO:0006805 9.93 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4 CYP3A5
3 aging GO:0007568 9.91 CYP1A1 HMGCR P2RY1 PTGS2
4 response to lipopolysaccharide GO:0032496 9.88 CYP1A1 CYP1A2 PTGS2 SELP
5 response to organic cyclic compound GO:0014070 9.85 CYP1A1 CYP1A2 PTGS2
6 platelet activation GO:0030168 9.85 ITGB3 P2RY1 P2RY12
7 response to organic substance GO:0010033 9.83 CYP1A1 CYP1A2 PTGS2
8 cellular response to organic cyclic compound GO:0071407 9.8 CYP1A1 P2RY1 P2RY12
9 omega-hydroxylase P450 pathway GO:0097267 9.8 CYP1A1 CYP1A2 CYP2C19 CYP2C9
10 oxidative demethylation GO:0070989 9.78 CYP1A2 CYP2C9 CYP3A4 CYP3A5
11 heterocycle metabolic process GO:0046483 9.73 CYP1A1 CYP1A2 CYP2C19 CYP3A4
12 organic acid metabolic process GO:0006082 9.72 CYP2C19 CYP2C9 CYP2J2
13 drug metabolic process GO:0017144 9.72 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4
14 cellular response to ATP GO:0071318 9.71 P2RY1 P2RY12 PTGS2
15 drug catabolic process GO:0042737 9.71 CYP1A2 CYP2C9 CYP3A4 CYP3A5
16 lipid hydroxylation GO:0002933 9.7 CYP1A1 CYP3A4 CYP3A5
17 response to immobilization stress GO:0035902 9.68 CYP1A1 CYP1A2
18 calcium-mediated signaling using intracellular calcium source GO:0035584 9.68 KDR SELP
19 monoterpenoid metabolic process GO:0016098 9.67 CYP1A2 CYP2C19 CYP2C9 CYP3A4
20 G protein-coupled purinergic nucleotide receptor signaling pathway GO:0035589 9.66 P2RY1 P2RY12
21 vitamin D metabolic process GO:0042359 9.66 CYP1A1 CYP3A4
22 glial cell migration GO:0008347 9.65 P2RY1 P2RY12
23 negative regulation of blood vessel diameter GO:0097756 9.65 HMGCR PTGS2
24 exogenous drug catabolic process GO:0042738 9.65 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
25 adenosine receptor signaling pathway GO:0001973 9.64 P2RY1 P2RY12
26 toxin metabolic process GO:0009404 9.63 CYP1A1 CYP1A2
27 hydrogen peroxide biosynthetic process GO:0050665 9.62 CYP1A1 CYP1A2
28 negative regulation of norepinephrine secretion GO:0010700 9.62 P2RY1 P2RY12
29 positive regulation of ion transport GO:0043270 9.61 P2RY1 P2RY12
30 porphyrin-containing compound metabolic process GO:0006778 9.6 CYP1A1 CYP1A2
31 steroid catabolic process GO:0006706 9.59 CYP1A2 CYP3A4
32 dibenzo-p-dioxin metabolic process GO:0018894 9.58 CYP1A1 CYP1A2
33 alkaloid catabolic process GO:0009822 9.57 CYP3A4 CYP3A5
34 monocarboxylic acid metabolic process GO:0032787 9.56 CYP1A2 CYP2C9
35 long-chain fatty acid biosynthetic process GO:0042759 9.55 CYP1A1 CYP1A2 CYP2C9 CYP3A4 PTGS2
36 epoxygenase P450 pathway GO:0019373 9.35 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2
37 steroid metabolic process GO:0008202 9.17 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
38 oxidation-reduction process GO:0055114 10.16 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
39 lipid metabolic process GO:0006629 10.04 CYP1A2 CYP2C9 CYP3A4 HMGCR PTGS2

Molecular functions related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.99 CYP1A1 CYP1A2 CYP2C19 CYP3A4 ITGB3 PTGS2
2 iron ion binding GO:0005506 9.87 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
3 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.8 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
4 oxygen binding GO:0019825 9.78 CYP1A1 CYP2C19 CYP3A4 CYP3A5
5 steroid hydroxylase activity GO:0008395 9.77 CYP1A1 CYP2C19 CYP2C9 CYP2J2 CYP3A4
6 heme binding GO:0020037 9.76 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
7 aromatase activity GO:0070330 9.73 CYP1A1 CYP1A2 CYP2J2 CYP3A5
8 arachidonic acid epoxygenase activity GO:0008392 9.7 CYP2C19 CYP2C9 CYP2J2
9 estrogen 16-alpha-hydroxylase activity GO:0101020 9.67 CYP1A1 CYP3A4 CYP3A5
10 caffeine oxidase activity GO:0034875 9.63 CYP1A2 CYP2C9 CYP3A4
11 G protein-coupled purinergic nucleotide receptor activity GO:0045028 9.56 P2RY1 P2RY12
12 demethylase activity GO:0032451 9.55 CYP1A1 CYP1A2
13 vitamin D 24-hydroxylase activity GO:0070576 9.54 CYP1A1 CYP3A4
14 monooxygenase activity GO:0004497 9.43 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
15 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.17 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
16 oxidoreductase activity GO:0016491 10.06 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4

Sources for Clopidogrel Resistance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....